Skip to content
PeptideGeek

Sexual health

PT-141 (Bremelanotide), explained simply

The first FDA-approved peptide that works through your brain to reignite sexual desire—think of it as flipping the 'on' switch for arousal rather than just boosting blood flow like traditional ED meds.

Well studied in peopleInjection under the skin (like insulin shots)7 cited sourcesResearch compound — not FDA approved

Start here

What is PT-141 (Bremelanotide)?

PT-141 (bremelanotide) is FDA approved for women with hypoactive sexual desire disorder (HSDD) — distressingly low sexual desire — after Phase 3 clinical trials 17. Unlike pills that boost blood flow, it works in the brain, activating melanocortin (a hormone system controlling pigment and appetite) receptors involved in desire and motivation. It is taken on demand, as an injection under the skin about 45 minutes before intimacy, rather than every day 7.

How it works in your body

Your brain has special receptors called melanocortin receptors that help control many things, including sexual desire. PT-141 activates these receptors, particularly one called MC4R, which is found in the part of your brain that controls motivation and reward. When PT-141 turns on these receptors, it triggers the release of dopamine—the 'feel good' chemical that makes you want things. Unlike Viagra, which just increases blood flow, PT-141 actually works on the 'wanting' part of your brain. It's like turning up the volume on your desire circuit rather than just making the plumbing work better.

The deeper mechanism, for the curious

Bremelanotide (PT-141) is a lab-made, ring-shaped peptide of 7 amino acids (a cyclic heptapeptide), Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH. 7 It switches on several melanocortin (a hormone system controlling pigment and appetite) receptors (docking sites that affect skin color, appetite and desire) without favoring just one (a non-selective agonist (a compound that switches a receptor on)). Its strength at them runs in this order: MC1R, MC4R, MC3R, MC5R, MC2R. At treatment doses, MC1R and MC4R matter most. 7 MC1R on melanocytes (skin pigment cells) explains the skin darkening. 7 The label states that how it improves desire in HSDD (low sexual desire) is unknown. 7 Animal studies suggest it may act on presynaptic MC4Rs (MC4 receptors on the sending end of nerve connections) in the medial preoptic area of the hypothalamus, which increases dopamine release (dopamine is a brain chemical linked to reward and motivation). 4 Its terminal half-life (the time for the last of the drug to halve in the body) is about 2.7 hours. Levels in the blood peak about 1 hour after injection, and about 100% of the dose gets into the bloodstream (bioavailability (how much actually gets absorbed and used)). 7

Evidence check

Well studied in people

This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.

Every numbered marker on this page links to one of the 7 sources at the bottom.

92/100

Sexual Desire

FDA approval was based on significant improvements in desire scores and reduced distress over low desire against placebo in two phase 3 trials.

95/100

On-Demand Use

Used as needed at least 45 minutes before sexual activity, with no daily dosing. How long each dose works is not known.

98/100

Clinical Evidence

One of the most thoroughly studied sexual health peptides, with Phase 3 trials, FDA approval, and long-term safety data

What the research points to

The most-asked question

How much PT-141 (Bremelanotide) do I take?

The research-reported range is 1.75 mg, as needed. Studies used different doses for different situations — find yours:

  1. Initial tolerance assessment, HSDD

    1 mg

    • How often
      As needed, ~45 min before sexual activity; no more than once per 24 h
    • For how long
      Trial period (assess response/tolerability)
    • How
      Injection under the skin

    Not a labelled dose: VYLEESI comes only as a 1.75 mg single-dose autoinjector 7. A 1 mg starting dose is community practice with compounded powder, used to gauge nausea. Inject into abdomen or thigh.

  2. Hypoactive sexual desire disorder, On-demand use

    1.75 mg

    • How often
      As needed, ~45 min before sexual activity; max once per 24 h and 8 doses per 28 days
    • For how long
      Ongoing as needed
    • How
      Injection under the skin

    FDA-approved Vyleesi dose for hypoactive sexual desire disorder in premenopausal women; efficacy shown in the RECONNECT phase 3 trials 16.

Every studied protocol, drawn on one scale — 0 to 1.75 mg.
  1. Initial tolerance assessment, HSDD1 mg
  2. Hypoactive sexual desire disorder, On-demand use1.75 mg

Adjusting your dose

You're at the right dose if…

  • Noticeable increase in sexual desire within 1-2 hours
  • Manageable or no nausea
  • Enhanced arousal response during intimacy
  • No significant blood pressure changes

Consider going up if…

  • You tolerate the starting dose with minimal nausea
  • Effects feel insufficient after multiple tries at current dose
  • Your healthcare provider recommends adjustment based on your response

Go down if…

  • Nausea is severe or interferes with the experience
  • You experience significant blood pressure increases
  • Flushing or headaches are uncomfortable
  • Side effects outweigh the benefits

The ceiling: 1.75 mg per dose (the only labelled dose); no more than one dose in 24 hours and no more than 8 doses per month 7

Reconstitution, in plain words

How do I mix PT-141 (Bremelanotide)?

Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for PT-141 (Bremelanotide):

What you need

  • Bacteriostatic water (BAC water)—contains preservative for multi-dose use
  • Insulin syringes (29-31 gauge) for injection
  • Alcohol swabs for cleaning vial tops and injection sites
  • Your PT-141 powder vial

A worked example

For a 10mg vial: add 2mL of BAC water to get 5mg/mL concentration. For the standard 1.75mg dose, you'd draw 0.35mL (35 units on an insulin syringe). For 2mg, draw 0.4mL (40 units).

Working out your dose

At 5mg/mL concentration: 1mg = 0.2mL (20 units); 1.75mg = 0.35mL (35 units); 2mg = 0.4mL (40 units). The FDA-approved Vyleesi autoinjector comes pre-dosed at 1.75mg and doesn't require reconstitution.

Or let the calculator do it

Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with PT-141 (Bremelanotide)'s recorded schedule.

PT-141 (Bremelanotide)As needed, ~45 min before sexual activity; no more than once per 24 h

How much peptide is in your bottle?

Look at the label on the vial. It’s the number next to the unit — like "5 mg". Labeled in IU? Switch the unit to IU.

Type a number to continue.
0

Injection sites & technique

Where do I inject PT-141 (Bremelanotide)?

The best spots

  • Abdomen (about 2 inches away from belly button)—FDA recommended site
  • Front or outer thigh (middle section)
  • Back of upper arm (if someone can help)

How to do it, step by step

  • Wash your hands thoroughly with soap and water
  • Clean the injection site with an alcohol swab and let it dry completely
  • If using a syringe: pinch about an inch of skin to create a fold
  • Insert the needle at a 45-90 degree angle (45 if lean, 90 if more tissue)
  • Inject slowly and steadily over a few seconds
  • Wait 5 seconds before withdrawing the needle
  • Apply light pressure with a clean cotton ball if needed—don't rub

Injection under the skin—this is how the FDA-approved Vyleesi autoinjector (a pen that gives a preset dose) delivers the dose

Timing

When do I take PT-141 (Bremelanotide)?

Best time of day

Inject at least 45 minutes before anticipated sexual activity. 7 How long each dose works is not known; the label lets each person choose the timing based on their own response and side effects such as nausea. 7

With or without food?

Taking PT-141 on an empty stomach may increase nausea. A light meal or snack beforehand can help reduce stomach upset without significantly affecting absorption.

Taking it with other peptides

PT-141 is typically used on its own. It works through melanocortin (a hormone system controlling pigment and appetite) receptors (brain targets for desire and arousal), so it doesn't directly interact with most other peptides, but check with your healthcare provider before combining it with other treatments.

The honest list

What side effects could PT-141 (Bremelanotide) cause?

Common — usually mild

These show up most often. They usually fade as your body adjusts.

Less common

Worth knowing about, but most people never see these.

  • Skin darkening (hyperpigmentation)

    PT-141 acts on melanocortin (a hormone system controlling pigment and appetite) receptors (targets that also control skin color). Some users notice darkening of the gums, face, or breasts with repeated use.

    What to do This is more common with frequent use and in people with darker skin tones. It may be permanent in some cases. Limit use to 8 doses per month as recommended.

Serious — stop and get medical help

Rare, but if any of these happen, stop and contact a medical professional.

Week by week

What should I expect from PT-141 (Bremelanotide), and when?

  1. First dose (Day 1)

    You might notice
    What's normal
    • Mild to moderate nausea that resolves on its own
    • Warmth in face and chest area
    • Gradual increase in feelings of desire or arousal
    • Subtle changes—this isn't an instant 'switch flip' for everyone
    What's next
    • Note your response to gauge future dosing
    • If nausea was severe, consider eating beforehand next time
    • Wait at least 24 hours before considering another dose
    • Many people find effects improve with experience

  2. First few uses

    You might notice
    • Nausea often decreases with repeated use
    • You learn your optimal timing (some need 60-90 minutes)
    • Effects may feel more predictable
    • Better understanding of what to expect
    What's normal
    • Some variation in effect from dose to dose
    • Learning what food/timing works best for you
    • Mild side effects that are manageable
    • Clearer sense of whether PT-141 is working for you
    What's next
    • Establish your personal protocol based on experience
    • Discuss with your healthcare provider if effects are inadequate
    • Stay within 8 doses per month maximum
    • Monitor for any skin changes with ongoing use

  3. Ongoing use (months)

    You might notice
    • Consistent effects if PT-141 works for you
    • Tolerance does not appear to develop significantly
    • Watch for potential skin hyperpigmentation
    • Continued manageable side effects
    What's normal
    • Stable response pattern over time
    • Continued mild nausea/flushing with each dose
    • No need to increase dose for same effect
    • Possible slight skin darkening in some areas
    What's next
    • Continue as prescribed by your healthcare provider
    • Regular check-ins to assess ongoing benefit vs. side effects
    • Report any concerning skin changes
    • Reevaluate periodically whether treatment is still needed

How to tell it's actually working

Sexual Desire Indicators

  • Increased spontaneous thoughts about intimacy
  • Greater interest in initiating sexual activity
  • Feeling more 'in the mood' than baseline
  • Reduced distress about low desire
  • More anticipation or excitement about intimacy

Physical Response Indicators

  • Enhanced physical arousal response
  • Improved natural lubrication (women)
  • Better erectile response (men, off-label use)
  • More satisfying intimate experiences overall
  • Body feels more 'responsive' to stimulation

Not seeing anything? The usual reasons

Is it right for you?

Who should avoid PT-141 (Bremelanotide)?

Do not use it if…

Be extra careful if…

When to stop

  • Severe nausea that makes the experience unpleasant or affects your health
  • Significant blood pressure increases, especially if you feel chest discomfort or severe headache
  • Noticeable skin darkening that concerns you (may be irreversible)
  • Any signs of allergic reaction—hives, swelling, difficulty breathing
  • The medication isn't providing the desired effect after multiple attempts
  • You become pregnant or are trying to conceive

PT-141 (Vyleesi) is an FDA-approved medication, but it should be used under healthcare provider supervision. This information is educational—always consult your doctor about starting, stopping, or adjusting any medication. Report any unexpected side effects to your healthcare provider.

What it mixes badly (and well) with

Medications

  • Avoid
    Blood pressure medications

    PT-141 affects blood pressure. Combining with antihypertensives (blood pressure medicines) may have unpredictable effects. Use only under medical supervision with monitoring.

  • Avoid
    Oral naltrexone

    Bremelanotide can significantly lower the level of naltrexone taken by mouth. Avoid combining it with naltrexone products for alcohol or opioid addiction, because the naltrexone treatment could fail 7

  • Avoid
    PDE5 inhibitors (Viagra, Cialis)

    Both affect the heart and blood vessels. They are sometimes combined in research for ED (erectile dysfunction), but this should only be done under medical supervision because their effects add together.

  • Avoid
    MAO inhibitors

    PT-141 affects the release of dopamine and norepinephrine (brain chemicals). MAOIs (a type of antidepressant) can dangerously amplify these effects. Avoid combining.

Other peptides

  • Avoid
    Melanotan II

    Both act on melanocortin (a hormone system controlling pigment and appetite) receptors (docking sites that affect skin color and desire). Combining them increases the risk of side effects including nausea, blood pressure changes, and skin darkening (hyperpigmentation). Avoid using together.

  • OK together
    Oxytocin

    May complement PT-141 by enhancing emotional bonding aspects of intimacy. Generally considered safe to combine, but research is limited.

  • OK together
    BPC-157

    No known direct interactions. BPC-157 works on different pathways (healing and gut health). Can likely be used in the same overall protocol.

Supplements

Who it tends to suit

Women with Low Sexual Desire (HSDD, hypoactive sexual desire disorder)

PT-141 is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder—when you used to have normal desire but it's faded, and it's causing real distress in your life. It's the only approved treatment that works through brain pathways rather than hormones.

Men Who Don't Respond to Viagra-Type Medications

While not FDA-approved for men, clinical research shows PT-141 may help men with erectile dysfunction who don't respond to PDE5 inhibitors like Viagra or Cialis. Because it works through the brain rather than blood vessels, it offers a completely different approach.

Those Wanting On-Demand Treatment

Unlike daily medications like flibanserin (Addyi), PT-141 is used only when you want it—take it 45 minutes before intimacy. This gives you control over timing without committing to daily pills.

People Seeking to Address the 'Wanting' Part of Intimacy

Many sexual health treatments focus on the physical mechanics (blood flow, lubrication). PT-141 is unique because it targets desire itself—the psychological 'wanting' that initiates intimacy. It works on your brain's arousal circuits.

The safety picture overall

PT-141 (bremelanotide) was approved by the FDA in 2019 as VYLEESI after two 24-week phase 3 trials in 1,247 premenopausal women. 17 Nausea was the most common reaction (40% vs 1% on placebo): it affected 21% after the first dose and about 3% after later doses, and 8% stopped treatment because of it. 7 Each dose raises blood pressure by up to 6/3 mmHg, peaking 2–4 hours after the dose, and lowers heart rate by up to 5 beats per minute, usually back to baseline within 12 hours. It is contraindicated in uncontrolled hypertension or known cardiovascular disease. 7 Focal hyperpigmentation occurred in 1% at up to 8 doses a month. 7 The 52-week open-label extension found no new safety signals. 2

PT-141 (as Vyleesi) has strong safety data from FDA-required Phase 3 trials and ongoing post-marketing surveillance. It's one of the most thoroughly studied peptides for sexual health. The clinical trials were conducted by Palatin Technologies and AMAG Pharmaceuticals with FDA oversight.

Keeping it good

How do I store PT-141 (Bremelanotide)?

Before mixing (powder)

Keep your PT-141 powder in the refrigerator (36-46°F / 2-8°C) for short-term storage or in the freezer (-4°F / -20°C) for long-term storage. Store in the original sealed vial away from light. Properly stored powder remains stable for 2+ years when frozen.

After mixing (liquid)

Compounded powder mixed with bacteriostatic water: refrigerate at 36-46°F (2-8°C), never freeze, keep away from light, and use within 30 days. The FDA-approved VYLEESI autoinjector is different: store it at or below 77°F (25°C), do not freeze, and protect it from light. 7

Signs it has gone bad

  • Cloudy or hazy appearance (should be crystal clear)
  • Visible particles floating or settled at the bottom
  • Color changes—any yellowing or discoloration
  • Unusual smell—fresh solution should have little to no odor

Not our opinion — the published record

What the studies actually found about PT-141 (Bremelanotide)

2019

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

The landmark RECONNECT trials that led to FDA approval. Over 1,200 premenopausal women with HSDD (low sexual desire that causes distress) showed improvements in sexual desire and reductions in distress, compared with placebo, that were large enough that chance is an unlikely explanation (statistically significant). The 1.75mg dose delivered real benefits where it mattered most.

Kingsberg SA, Clayton AH, Portman D

2019

Bremelanotide: First Approval

This comprehensive review covered PT-141's journey from lab to FDA approval. It explained how the drug works on MC4 receptors (docking sites on brain cells) in the brain's desire circuits, a completely new mechanism compared with existing sexual health treatments.

Dhillon S, Keam SJ

2019

VYLEESI (bremelanotide injection) US Prescribing Information

Original 2019 VYLEESI label: 1.75 mg injected under the skin with an autoinjector (a pen that gives a preset dose) at least 45 minutes before sexual activity, at most once in 24 hours and 8 times a month, for premenopausal women with acquired, generalized HSDD (low sexual desire that is not lifelong and is not tied to a particular situation or partner).

AMAG Pharmaceuticals (FDA)

2025

VYLEESI (bremelanotide injection) — US Prescribing Information (current DailyMed)

For premenopausal women with acquired, generalized HSDD (low sexual desire that is not lifelong and is not tied to a particular situation or partner). Not approved for postmenopausal women, men, or to enhance sexual performance. 1.75 mg by autoinjector (a pen that gives a preset dose) at least 45 minutes before sexual activity; at most one dose in 24 hours and 8 per month; stop after 8 weeks without improvement. Must not be used with uncontrolled high blood pressure or known heart or blood vessel disease. Blood pressure rises by up to 6/3 mmHg (peak 2-4 h) and heart rate falls by up to 5 bpm (beats per minute), returning to normal within 12 h. Nausea 40% (21% after the first dose, about 3% after later doses), flushing 20%, injection-site reactions 13%, headache 11%, vomiting 5%. Focal hyperpigmentation (patches of skin darkening) 1% at up to 8 doses a month, 38% with 8 daily doses. Lowers levels of naltrexone taken by mouth. How it works in HSDD is unknown; the most relevant receptors are MC1R and MC4R. Store at or below 25 C.

Cosette Pharmaceuticals / U.S. Food and Drug Administration

If this isn't the right fit

What people use instead of PT-141 (Bremelanotide)

Daily treatment for low female desire

  • Flibanserin (Addyi)
  • Testosterone therapy (off-label, meaning not for its approved purpose)
  • Psychotherapy/sex therapy

Erectile dysfunction in men (trouble getting or keeping an erection)

  • Sildenafil (Viagra)
  • Tadalafil (Cialis)
  • Alprostadil
  • PT-141 (off-label use, meaning not for its approved purpose; still being researched)

Enhancing intimacy without injections

  • Oxytocin nasal spray
  • Flibanserin oral tablets
  • Lifestyle modifications

Your questions

PT-141 (Bremelanotide) FAQ

How is PT-141 different from Viagra or Cialis?

Viagra and Cialis work by increasing blood flow to the genitals. They help with the physical mechanics of arousal but don't affect desire. PT-141 works in your brain, switching on targets (receptors) that control motivation and wanting. It's the difference between the plumbing working and actually wanting to be intimate in the first place. That's why PT-141 can help people whose bodies work fine but who've lost the "spark" of desire.

Will PT-141 make me feel aroused all the time?

No—PT-141 enhances your natural desire response rather than creating constant arousal. You'll likely feel more receptive to intimacy and more easily aroused when appropriate situations arise, but you won't be walking around in a constant state of arousal. Think of it as lowering the threshold for desire, not forcing it.

Why does PT-141 cause nausea?

The label does not explain why. Nausea is most common after the first dose (21%) and falls to about 3% with later doses. 7 Pre-treatment with ondansetron did not reduce it, and the label does not recommend that. 7 The 1.75 mg autoinjector is the only labelled dose. 7

Can men use PT-141?

While PT-141 is only FDA-approved for women with HSDD, research has shown it can help men with erectile dysfunction—particularly those who don't respond to Viagra-type medications. Clinical trials in men have shown positive results, and Palatin Technologies is actively developing it for male ED. Currently, men would be using it off-label.

How often can I use PT-141?

The FDA recommends no more than one dose per 24 hours and no more than 8 doses per month. This isn't about building tolerance (which doesn't seem to happen), but about limiting cumulative side effects like skin hyperpigmentation and ensuring cardiovascular safety.

Will PT-141 darken my skin permanently?

PT-141 can cause patchy darkening of the gums, face, or breasts with repeated use, especially in people with darker skin tones. This happens because melanocortin (a hormone system controlling pigment and appetite) receptors (the drug's targets) also control skin color. In some cases, the darkening may not fully fade. Staying within the recommended limit of 8 doses per month helps lower this risk.

Can I take PT-141 with alcohol?

In a study in the label, alcohol did not change bremelanotide levels. Flushing was no more common than with bremelanotide alone, but headache was more common with the combination. 7 Alcohol can also dampen sexual response, so keeping intake moderate makes sense.

Is the Vyleesi autoinjector (a pen that gives a preset dose) the only way to take PT-141?

The FDA-approved form (Vyleesi) comes as a pre-filled autoinjector that's simple to use. However, compounding pharmacies also provide PT-141 as lyophilized powder that you reconstitute and inject yourself with insulin syringes. The active ingredient is the same, but only the Vyleesi autoinjector has FDA approval.

7 sources

References

Every numbered marker on this page points to one of these. Same sources, same numbering as the PT-141 (Bremelanotide) research profile on Peptide Initiative.

  1. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsKingsberg SA, Clayton AH, Portman D · 2019
  2. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderSimon JA, Kingsberg SA, Portman D · 2019
  3. Bremelanotide: First ApprovalDhillon S, Keam SJ · 2019
  4. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal womenPfaus JG, Sadiq A, Spana C · 2022
  5. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study ResultsKoochaki P, Revicki D, Wilson H · 2021
  6. VYLEESI (bremelanotide injection) US Prescribing InformationAMAG Pharmaceuticals (FDA) · 2019
  7. VYLEESI (bremelanotide injection) — US Prescribing Information (current DailyMed)Cosette Pharmaceuticals / U.S. Food and Drug Administration · 2025

Want the deep science?

Read the full PT-141 (Bremelanotide) research profile

Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.

Open the research profile

More sexual health guides

This guide is education, not medical advice. PT-141 (Bremelanotide) is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.